FDA rejects MDMA therapy for PTSD

The FDA rejected Lykos Therapeutics' application for MDMA-assisted therapy for PTSD, citing methodological concerns. A setback for the psychedelic-assisted psychotherapy movement.

Psychedelic research has experienced a renaissance after decades of restrictions. Rigorous clinical trials have shown that substances like psilocybin and MDMA, combined with structured psychotherapy, can produce significant improvements in treatment-resistant depression, PTSD, and addiction. The mechanism likely involves enhancement of neuronal plasticity and temporary increases in connectivity between brain networks.

The 2020s have been marked by the COVID-19 pandemic, the rise of online psychotherapy, and growing interest in mental health. Psychology has responded with rapid innovation in treatment formats and greater attention to social determinants of mental health.

Significance: This milestone significantly contributed to the development of psychology as a science and profession, influencing research, clinical practice, or public policy.